A first-in-human phase i dose-escalation trial of the novel therapeutic peptide, alm201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours

HIGHLIGHTS

• who: Aya El Helali from the Received: , May , Revised: , February , Accepted: , March , Published online: , May , Published on Behalf of CR UK have published the paper: A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours, in the Journal: (JOURNAL)
• what: The authors report the first-in-human trial with ALM201. The aims of this study were to characterise the safety and tolerability of ALM201 in patients with solid tumours.
• how: Pharmacokinetic parameters . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.